An ex vivo technique using nasal epithelial cells from a young girl carrying a rare mutation profile for cystic…
Vanda Pinto, PhD
​​Vanda is a biochemist with a PhD in biomedicine from the University of Porto, Portugal. She conducted her postdoctoral research first at the Bristol Medical School, U.K., studying the insulin-PI3K/Akt signaling pathway in diabetic nephropathy, then at the Institute of Molecular Pathology and Immunology of the University of Porto, where her focus was on glycosylation in lupus nephritis and inflammatory bowel disease. She next made the switch to science publishing, handling papers in biochemistry, molecular biology, and immunology.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Vanda Pinto, PhD
A clinical trial underway in Israel is investigating how well a personalized chest physiotherapy system compares with traditional airway clearance techniques…
Thirona announced it has developed a new software program that can quickly detect and quantify lung anomalies in…
Translate Bio’s ongoing Phase 1/2 clinical trial investigating MRT5005, its candidate inhalation therapy for cystic fibrosis (CF), found that…
An enzyme produced using computer design, in combination with the antibiotic tobramycin, efficiently kills Pseudomonas aeruginosa, a pathogen that…
Thanks to the Cystic Fibrosis Foundation (CFF), people with cystic fibrosis (CF) in the United States will receive free…